临床试验/CTIS2023-503909-11-01

CTIS2023-503909-11-01进行中（未招募）1 期

KAN0008

Kancera AB0 个研究点目标入组 88 人开始时间: 2023年8月18日最近更新: 2024年7月22日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Kancera AB
入组人数: 88

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 64（—）
性别: All

入选标准

未提供

排除标准

未提供

研究者

发起方

相似试验

进行中（未招募）

Phase I, double-blind, randomized, placebo-controlled study investigating the safety, tolerability and concentrations of the study product KAND145 in healthy volunteersMedDRA version: 20.0Level: PTClassification code: 10033128Term: Ovarian cancer Class: 100000004864Ovarian cancer

CTIS2023-503909-11-00Kancera AB80

进行中（未招募）

Assessment of the influence of the gut microbiome on tacrolimus pharmacokinetics in healthy volunteers

CTIS2023-504405-37-00niversitaetsklinikum Heidelberg AöR20

进行中（未招募）

First-in-human (FIH), microdosing, non-randomized, clinical trial to investigate binding of positron emission tomography tracer [68Ga]Ga-DOTA-Cys-ATH001 targeting platelet derived growth factor receptor ß in healthy subjects as compared to patients with metabolic dysfunction-associated steatohepatitis (MASH) and Primary Sclerosing Cholangitis binding (PSC, liver) and patients with fibrostenotic Crohn’s disease (CD, gastrointestinal tract [GI])Metabolic dysfunction-associated steatotic liver disease, Crohn’s disease, Primary Sclerosing CholangitisMedDRA version: 24.1Level: LLTClassification code: 10086076Term: Fibrostenotic Crohn´s disease Class: 100000004848MedDRA version: 20.0Level: PTClassification code: 10076331Term: Steatohepatitis Class: 100000004871MedDRA version: 20.1Level: LLTClassification code: 10036732Term: Primary sclerosing cholangitis Class: 10019805

CTIS2023-506555-15-00Antaros Medical AB30

Investigation of safety, tolerability and pharmacokinetics of multiple doses of NNC0113-6856 in healthy participants, including a subset of healthy Japanese participantsType 2 diabetesMedDRA version: 21.1Level: LLTClassification code: 10045242Term: Type II diabetes mellitus Class: 10027433

CTIS2023-503891-26-00ovo Nordisk A/S170

进行中（未招募）

A study to learn more about how BAY3283142 moves into, through, and out of the body of healthy participants when taken together with atazanavir and to assess the proportion of BAY3283142 that reaches the blood when taken by mouth.MedDRA version: 20.1Level: LLTClassification code: 10054109Term: Non-proliferative diabetic retinopathy Class: 10015919MedDRA version: 23.1Level: PTClassification code: 10064848Term: Chronic kidney disease Class: 100000004857Chronic kidney disease

CTIS2024-510856-11-00Bayer AG15